---
title: "Hengrui Pharma's subsidiary HRS9531 injection has been approved to conduct clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283369093.md"
description: "Hengrui Pharma announced that its subsidiary Fujian Shengdi's HRS9531 injection has been approved by the National Medical Products Administration. This product will conduct clinical trials in overweight and obese adolescents. The marketing application for HRS9531 for long-term weight management in adults was accepted by the National Medical Products Administration in September 2025"
datetime: "2026-04-20T14:15:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283369093.md)
  - [en](https://longbridge.com/en/news/283369093.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283369093.md)
---

# Hengrui Pharma's subsidiary HRS9531 injection has been approved to conduct clinical trials

Hengrui Pharma (01276.HK) announced that its subsidiary Fujian Shengdi's HRS9531 injection has been approved by the National Medical Products Administration. This product will conduct clinical trials in overweight and obese adolescents. The marketing application for HRS9531 for long-term weight management in adults was accepted by the National Medical Products Administration in September 2025

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth | KLRA Stock News](https://longbridge.com/en/news/283635919.md)
- [Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate Cancers](https://longbridge.com/en/news/283735850.md)
- [Long Investment Corp Details Financial Profiles of Nasdaq Targets in Share Purchase Deals](https://longbridge.com/en/news/283463704.md)
- [CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/283937737.md)
- [20:53 ETKelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting](https://longbridge.com/en/news/283576388.md)